Galectin Therapeutics Inc. (GALT) is priced at $2.55 after the most recent trading session. At the very opening of the session, the stock price was $2.28 and reached a high price of $2.32, prior to closing the session it reached the value of $2.16. The stock touched a low price of $2.14.
Recently in News on April 14, 2021, Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy. Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone. You can read further details here
Galectin Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.27 on 04/06/21, with the lowest value was $1.82 for the same time period, recorded on 01/27/21.
Galectin Therapeutics Inc. (GALT) full year performance was 13.95%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Galectin Therapeutics Inc. shares are logging -33.77% during the 52-week period from high price, and 54.08% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.65 and $3.85.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 37528858 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Galectin Therapeutics Inc. (GALT) recorded performance in the market was -3.35%, having the revenues showcasing -2.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 118.58M, as it employees total of 6 workers.
The Analysts eye on Galectin Therapeutics Inc. (GALT)
During the last month, 0 analysts gave the Galectin Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.35, with a change in the price was noted -0.14. In a similar fashion, Galectin Therapeutics Inc. posted a movement of -5.13% for the period of last 100 days, recording 832,641 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for GALT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Galectin Therapeutics Inc. (GALT)
Raw Stochastic average of Galectin Therapeutics Inc. in the period of last 50 days is set at 46.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 46.02%. In the last 20 days, the company’s Stochastic %K was 26.32% and its Stochastic %D was recorded 29.89%.
Considering, the past performance of Galectin Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -3.35%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -20.99%, alongside a boost of 13.95% for the period of the last 12 months. The shares increased approximately by -22.68% in the 7-day charts and went down by -6.28% in the period of the last 30 days. Common stock shares were lifted by -2.04% during last recorded quarter.